Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

337 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Tau pathology and future therapeutics.
Gozes I. Gozes I. Curr Alzheimer Res. 2010 Dec;7(8):685-96. doi: 10.2174/156720510793611628. Curr Alzheimer Res. 2010. PMID: 20678069 Review.
Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock.
Gozes I, Lilling G, Davidson A, Bardea A, Reshef A, Glazer R, Zamostiano R, Ashur-Fabian O, Ticher A, Ashkenazi IE, Moody TW, Rubinraut S, Fridkin M, Brenneman DE. Gozes I, et al. Ann N Y Acad Sci. 1996 Dec 26;805:159-69; discussion 169-71. doi: 10.1111/j.1749-6632.1996.tb17481.x. Ann N Y Acad Sci. 1996. PMID: 8993401 Review. No abstract available.
Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.
Gozes I, Perl O, Giladi E, Davidson A, Ashur-Fabian O, Rubinraut S, Fridkin M. Gozes I, et al. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4143-8. doi: 10.1073/pnas.96.7.4143. Proc Natl Acad Sci U S A. 1999. PMID: 10097177 Free PMC article.
Pharmaceutical VIP: prospects and problems.
Gozes I, Fridkinb M, Hill JM, Brenneman DE. Gozes I, et al. Curr Med Chem. 1999 Nov;6(11):1019-34. Curr Med Chem. 1999. PMID: 10519911 Review.
A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.
Gozes I, Bassan M, Zamostiano R, Pinhasov A, Davidson A, Giladi E, Perl O, Glazner GW, Brenneman DE. Gozes I, et al. Ann N Y Acad Sci. 1999;897:125-35. doi: 10.1111/j.1749-6632.1999.tb07884.x. Ann N Y Acad Sci. 1999. PMID: 10676441 Review.
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Offen D, Sherki Y, Melamed E, Fridkin M, Brenneman DE, Gozes I. Offen D, et al. Among authors: gozes i. Brain Res. 2000 Jan 31;854(1-2):257-62. doi: 10.1016/s0006-8993(99)02375-6. Brain Res. 2000. PMID: 10784133
A new concept in the pharmacology of neuroprotection.
Gozes I, Brenneman DE. Gozes I, et al. J Mol Neurosci. 2000 Feb-Apr;14(1-2):61-8. doi: 10.1385/JMN:14:1-2:061. J Mol Neurosci. 2000. PMID: 10854037 Review.
A novel peptide prevents death in enriched neuronal cultures.
Zemlyak I, Furman S, Brenneman DE, Gozes I. Zemlyak I, et al. Among authors: gozes i. Regul Pept. 2000 Dec 22;96(1-2):39-43. doi: 10.1016/s0167-0115(00)00198-1. Regul Pept. 2000. PMID: 11102650
A novel VIP responsive gene. Activity dependent neuroprotective protein.
Gozes I, Zamostiano R, Pinhasov A, Bassan M, Giladi E, Steingart RA, Brenneman DE. Gozes I, et al. Ann N Y Acad Sci. 2000;921:115-8. doi: 10.1111/j.1749-6632.2000.tb06957.x. Ann N Y Acad Sci. 2000. PMID: 11193814
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.
Sigalov E, Fridkin M, Brenneman DE, Gozes I. Sigalov E, et al. Among authors: gozes i. J Mol Neurosci. 2000 Dec;15(3):147-54. doi: 10.1385/JMN:15:3:147. J Mol Neurosci. 2000. PMID: 11303779
337 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback